The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Segluromet ertugliflozin;metformin hydrochloride | Merck Sharp & Dohme B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2018-03-23 | Order → |
| Semglee insulin glargine Biosimilar | Biosimilar Collaborations Ireland Limited | Diabetes Mellitus | 🇪🇺 EU 2018-03-23 | Order → |
| Steglujan ertugliflozin;sitagliptin | Merck Sharp & Dohme B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2018-03-23 | Order → |
| Lokelma sodium zirconium cyclosilicate | AstraZeneca AB | Hyperkalemia | 🇪🇺 EU 2018-03-22 | Order → |
| Shingrix herpes zoster vaccine (recombinant, adjuvanted) | GlaxoSmithKline Biologicals S.A. | Herpes Zoster | 🇪🇺 EU 2018-03-21 | Order → |
| Steglatro ertugliflozin | Merck Sharp & Dohme B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2018-03-21 | Order → |
| Hemlibra emicizumab Accelerated assessment | Roche Registration Limited | Hemophilia A | 🇪🇺 EU 2018-02-23 | Order → |
| Crysvita burosumab Orphan | Kyowa Kirin Holdings B.V. | Hypophosphatemia, Familial; Hypophosphatemic Rickets, X-Linked Dominant; Osteomalacia | 🇪🇺 EU 2018-02-19 | Order → |
| Anagrelide Viatris (previously Anagrelide Mylan) anagrelide Generic | Viatris Limited | Thrombocythemia, Essential | 🇪🇺 EU 2018-02-15 | Order → |
| Alkindi hydrocortisone | Immedica Pharma AB | Adrenal Insufficiency | 🇪🇺 EU 2018-02-09 | Order → |
| Herzuma trastuzumab Biosimilar | Celltrion Healthcare Hungary Kft. | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 2018-02-09 | Order → |
| Efavirenz/Emtricitabine/Tenofovir disoproxil Krka efavirenz;emtricitabine;tenofovir disoproxil Generic | KRKA tovarna zdravil d.d. Novo mesto | HIV Infections | 🇪🇺 EU 2018-02-08 | Order → |
| Ozempic semaglutide | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2018-02-08 | Order → |
| Darunavir Krka darunavir Generic | KRKA tovarna zdravil d.d. Novo mesto | HIV Infections | 🇪🇺 EU 2018-01-26 | Order → |
| Darunavir Krka d.d. darunavir Generic | KRKA tovarna zdravil d.d. Novo mesto | HIV Infections | 🇪🇺 EU 2018-01-18 | Order → |
| Mvasi bevacizumab Biosimilar | Amgen Europe B.V. | Carcinoma, Renal Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms | 🇪🇺 EU 2018-01-15 | Order → |
| Adynovi rurioctocog alfa pegol Additional monitoring | Baxalta Innovations GmbH | Hemophilia A | 🇪🇺 EU 2018-01-08 | Order → |
| Fasenra benralizumab | AstraZeneca AB | Asthma | 🇪🇺 EU 2018-01-08 | Order → |
| Fulvestrant Mylan fulvestrant Generic | Mylan Pharmaceuticals Limited | Breast Neoplasms | 🇪🇺 EU 2018-01-08 | Order → |
| Intrarosa prasterone | Endoceutics S.A. | Postmenopause | 🇪🇺 EU 2018-01-08 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.